The last 5 years have seen the emergence of efficacious peptide-based therapies for obesity treatment that target glucagon-like peptide-1 receptor (GLP-1R), either selectively or via co-activation with related receptors, such as the glucose-dependent insulinotropic polypeptide and/or glucagon receptors 1
While originally studied in injectable form, advancements in peptide science have led to the development of oral versions that seek to provide similar benefits through daily supplementation
68- AP/NTS: 1525%
Laboratory and Metabolic Parameters Clinical trials have monitored various metabolic and safety parameters [9] : Contraindications & Precautions Research Protocol Exclusion Criteria (from clinical trials) History of pancreatitis (acute or chronic) Pre-existing gastroparesis or severe gastrointestinal disease Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) History of diabetic ketoacidosis Severe renal impairment (eGFR 99% as verified by High-Performance Liquid Chromatography (HPLC) Third-Party Testing: Independent laboratory verification with Certificate of Analysis (COA) included Lyophilized Form: Stable powder format for extended shelf life and easy reconstitution Proper Storage: Maintained at -20C to preserve peptide integrity USA Manufactured: Produced in domestic facilities following Good Manufacturing Practices (GMP) [18]
Kucerova L, Demkova L, Skolekova S, Bohovic R, Matuskova M
Human Psychopharmacology: Clinical and Experimental, 38 (3), e2872
